Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16635679 | 1.00 | CTSK (0.41) | CTSKCHEK1PIM1DYRK1AGSK3B | |
| SCHEMBL16635677 | 0.93 | CTSK (0.48) | CTSKCHEK1PIM1DYRK1AGSK3B | |
| SCHEMBL16635716 | 0.93 | CTSK (0.48) | CTSKCHEK1PIM1DYRK1AGSK3B | |
| SCHEMBL16635866 | 0.91 | CTSK (0.41) | CTSKCHEK1PIM1DYRK1AGSK3B | |
| SCHEMBL16636184 | 0.89 | CTSK (0.43) | CTSKCHEK1PIM1DYRK1AGSK3B | |
| SCHEMBL16635786 | 0.89 | CTSK (0.43) | CTSKCHEK1PIM1DYRK1AGSK3B | |
| SCHEMBL16635725 | 0.85 | CTSK (0.60) | CTSKDYRK1AGSK3B | |
| SCHEMBL16637706 | 0.85 | CTSK (0.35) | CTSKPIM1DYRK1AGSK3B | |
| SCHEMBL16635865 | 0.84 | CTSK (0.47) | CTSKCHEK1PIM1DYRK1AGSK3B | |
| SCHEMBL16635788 | 0.82 | CTSK (0.50) | CTSKCHEK1PIM1DYRK1AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3054947-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-17 | — | — | EP | disclosed |
| US-9573913-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160244417-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3054947-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015054038-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244417-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | CTSK 4/4885CHEK1 2179/4885PIM1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.